New Insights Into Ovarian Cancer: Why Whole-Genome Doubling May Hold the Key to Future HGSOC Treatment Strategies
Whole‑genome doubling‑high (WGD‑high) ovarian cancers suppress immune responses through repression of the STING pathway, indicating that WGD could be a target for novel therapies.
High‑grade serous ovarian carcinoma (HGSOC) frequently undergoes whole‑genome doubling (WGD). In a single‑cell sequencing cohort of 70 tumors from 41 patients with untreated HGSOC, 65% were classified as WGD‑high. Compared with WGD‑low lesions, WGD‑high tumors exhibited robust suppression of the innate immune STING signaling pathway, likely through mechanisms that dampen micronuclei‑induced DNA‑cytoplasmic sensing. Comprehensive mapping of WGD events revealed that these duplications can arise early or late during tumor evolution and may occur multiple times within a single tumor. These findings suggest that targeting WGD‑related mechanisms could enhance immune effector function in HGSOC and provide a rationale for developing therapies that specifically disrupt WGD‑mediated immune evasion.
Understanding that WGD‑high tumors actively suppress STING‑mediated immunity highlights a new vulnerability in HGSOC that could be exploited therapeutically. Targeted disruption of WGD‑associated immune suppression may improve responses to immunotherapy and overcome resistance seen in advanced ovarian cancer, which remains a leading cause of female cancer mortality.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Scientists discover why cancer drugs don’t work for everyone
- Epithelial ovarian cancer: prevention, diagnosis, and treatment
- Gynecologic Cancer InterGroup Consensus Recommendations on Clinical Research in Ovarian Cancer
- Why anti‑estrogen therapy fails in ovarian cancer, and how to make it work
- Paradigm Shift: A Comprehensive Review of Ovarian Cancer Management in an Era of Advancements